Ausgabe Sonderheft 1/2005
Inhalt (11 Artikel)
Original Article
Decitabine: a historical review of the development of an epigenetic drug
Dick de Vos, Wendy van Overveld
Original Article
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
P. W. Wijermans, M. Lübbert, G. Verhoef, V. Klimek, A. Bosly
Original Article
Clinical experience with decitabine in North American patients with myelodysplastic syndrome
Karen W. L. Yee, Elias Jabbour, Hagop M. Kantarjian, Francis J. Giles
Original Article
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
J. A. Pitako, P. S. Haas, J. Van den Bosch, H. Müller-Berndorff, A. Kündgen, U. Germing, P. W. Wijermans, M. Lübbert
Original Article
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies
Björn Hackanson, Christian Robbel, Pierre Wijermans, Michael Lübbert
Original Article
Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia
Oliver Galm, Stefan Wilop, Christian Lüders, Edgar Jost, Gerald Gehbauer, James G. Herman, Rainhardt Osieka
Original Article
Decitabine activates specific caspases downstream of p73 in myeloid leukemia
Ingo Tamm, Mandy Wagner, Karin Schmelz
Original Article
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts
Antonella Gozzini, Valeria Santini
Original Article
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
Andrea Kuendgen, Sabine Knipp, Frank Fox, Corinna Strupp, Barbara Hildebrandt, Christian Steidl, Ulrich Germing, Rainer Haas, Norbert Gattermann
Original Article
The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia
Hans Eckart Schaefer, Michael Lübbert